
Penumbra (PEN) Stock Forecast & Price Target
Penumbra (PEN) Analyst Ratings
Bulls say
Penumbra is a leading biomedical devices and services company, specializing in minimally invasive endovascular treatments for neurovascular and peripheral vascular disorders. The company has seen impressive growth in recent years, with preliminary Q4/25 revenue expected to be in the range of $383.0M-$384.8M (+21.4%-+22.0% Y/Y) and a strong operating margin of 14.8%-15.7%. While the recent acquisition by Boston Scientific (BSX) may lead to concerns about competition and potential antitrust issues, Penumbra's differentiated technology platform and continued innovation make it well-positioned to maintain and potentially increase its market share in the fast-evolving acute ischemic stroke treatment market.
Bears say
Penumbra is being acquired by Boston Scientific in a stock-and-cash transaction for $374 per share, which values the company at approximately $14.5 billion. While this acquisition has been the subject of speculation for some time, and Penumbra's flagship product has been gaining market share and has strong clinical evidence, there are potential risks from patent and product liability litigation, as well as the company's heavy reliance on new product introductions and competitive markets. Additionally, Boston Scientific itself faces challenges with patent litigation and product liability, as well as the potential for deterioration in its CRM and DES businesses and risks associated with numerous acquisitions.
This aggregate rating is based on analysts' research of Penumbra and is not a guaranteed prediction by Public.com or investment advice.
Penumbra (PEN) Analyst Forecast & Price Prediction
Start investing in Penumbra (PEN)
Order type
Buy in
Order amount
Est. shares
0 shares